RARE - Ultragenyx Pharmaceutical Inc.
44.87 +0.11 (0.25%)
After hours: 4:11PM EDT
| Previous Close | 44.10 |
| Open | 43.71 |
| Bid | 44.82 x 1100 |
| Ask | 44.98 x 800 |
| Day's Range | 43.46 - 45.71 |
| 52 Week Range | 37.44 - 90.98 |
| Volume | 458,607 |
| Avg. Volume | 502,077 |
| Market Cap | 2.582B |
| Beta (3Y Monthly) | 2.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GuruFocus.com
Ultragenyx Pharmaceutical Inc (RARE) President & CEO Emil D Kakkis Bought $218,150 of Shares
President & CEO of Ultragenyx Pharmaceutical Inc (30-Year Financial, Insider Trades) Emil D Kakkis (insider trades) bought 5,000 shares of RARE on 09/11/2019 at an average price of $43.63 a share. Continue reading...
- Zacks
Ultragenyx to Submit sBLA for Label Expansion of Crysvita
Ultragenyx (RARE) and partner Kyowa Kirin plan to submit an sBLA to the FDA for the label expansion of Crysvita.
- Zacks
Ultragenyx-GeneTx Get Orphan Drug Status for GTX-102 From FDA
The FDA grants Orphan Drug and Rare Pediatric Disease designations to Ultragenyx (RARE) and partner GeneTx Biotherapeutics' GTX-102 for the treatment of Angelman Syndrome.
- Simply Wall St.
Is Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Trading At A 36% Discount?
Does the September share price for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) reflect what it's really worth? Today...
- Zacks
Ultragenyx (RARE) Down 9.9% Since Last Earnings Report: Can It Rebound?
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Ultragenyx (RARE) Focuses on Pipeline Amid Low Revenues
Ultragenyx (RARE) focuses on the development of pipeline candidates. Being a new commercial company with lower revenues, development or regulatory setbacks could result in higher operating expenses.
- Investor's Business Daily
This Biotech Stock Just Roped In A New Partner — And A Potential Buyout
Ultragenyx Pharmaceutical will pay $20 million to partner with — and potentially acquire — biotech startup GeneTx as it studies a treatment for a rare disease called Angelman syndrome.
- Zacks
Amicus (FOLD) Q2 Earnings Match, Stock Falls on Weak Q3 View
Amicus' (FOLD) earnings meet estimates in the second quarter while revenues beat the same.
- Thomson Reuters StreetEvents
Edited Transcript of RARE earnings conference call or presentation 1-Aug-19 9:00pm GMT
Q2 2019 Ultragenyx Pharmaceutical Inc Earnings Call
- Zacks
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q2
Ultragenyx (RARE) posts wider-than-expected loss but beats on sales in the second quarter of 2019.
Motley FoolUltragenyx Pharmaceutical Inc (RARE) Q2 2019 Earnings Call Transcript
RARE earnings call for the period ending June 30, 2019.
- Zacks
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates
Ultragenyx (RARE) delivered earnings and revenue surprises of -6.94% and 11.33%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Why Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Is A Financially Healthy Company
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Ultragenyx...
- Zacks
Arcturus Metabolic Disorder Candidate Gets Orphan Drug Status
The FDA grants orphan drug designation to Arcturus Therapeutics' (ARCT) candidate, ARCT-810 for treating patients with ornithine transcarbamylase deficiency, the most common urea cycle disorder.
- American City Business Journals
Health Care Digest: How California's stem cell institute may help find glaucoma cure; a stealthy biotech with $100M; and more
The future of California's stem cell research funding agency is in doubt, but its impact goes far beyond the billions of dollars it has doled out to researchers, says the Glaucoma Research Foundation.
- Zacks
Ultragenyx & Arcturus Therapeutics Expand Existing Agreement
Ultragenyx (RARE) and Arcturus Therapeutics expand their existing collaboration to discover and develop mRNA, DNA and siRNA therapeutics for up to 12 rare disease targets.
- Insider Monkey
Here’s What Hedge Funds Think About Ultragenyx Pharmaceutical Inc (RARE)
Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients' money, and needless to say, they are painstakingly thorough when analyzing where to invest this money, as their own wealth also depends on it. Regardless of the various methods used by elite investors like David Tepper and David […]
- Markit
See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RAREView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for RARE with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding RARE are favorable, with net inflows of $2.42 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- American City Business Journals
'Something worth doing': How a biotech entrepreneur grew a 700-person company and is conquering rare diseases
Emil Kakkis launched Ultragenyx Pharmaceutical in Novato and the EveryLife Foundation for Rare Diseases, lobbying for legislative changes to make it easier to develop rare disease drugs.
- Zacks
Ultragenyx (RARE) Down 5.7% Since Last Earnings Report: Can It Rebound?
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
Is Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Paid At A Competitive Rate?
In 2010 Emil Kakkis was appointed CEO of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). This analysis aims first to...
- Thomson Reuters StreetEvents
Edited Transcript of RARE earnings conference call or presentation 6-May-19 9:00pm GMT
Q1 2019 Ultragenyx Pharmaceutical Inc Earnings Call
